ArriVent BioPharma/$AVBP

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About ArriVent BioPharma

ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.

Ticker

$AVBP
Sector
Health
Primary listing
NASDAQ

Employees

-
Headquarters
Newtown Square, United States
Website
arrivent.com

AVBP Metrics

BasicAdvanced
$811M
-
-$4.02
-
-

What the Analysts think about AVBP

Analyst ratings (Buy, Hold, Sell) for ArriVent BioPharma stock.

Bulls say / Bears say

ArriVent has completed enrollment for its pivotal Phase 3 FURVENT trial for furmonertinib in first-line EGFR exon 20 insertion NSCLC, with 398 patients globally, and expects to report topline data in early 2026. This represents a significant de-risking milestone, with Wall Street analysts maintaining a strong buy consensus (Investing.com).
Interim Phase 1b PACC data have confirmed furmonertinib’s activity in EGFR PACC mutant NSCLC, and ArriVent expects to enroll the first patient in the pivotal Phase 3 ALPACCA study in the second half of 2025, highlighting strategic diversification beyond exon 20 insertions (ArriVent Q2 2025 Results).
As of June 30, 2025, ArriVent had $254.5 million in cash and investments, and raised an additional $81.1 million in July 2025, providing funding through mid-2027, which reduces near-term dilution risk for its ongoing development programs (ArriVent Q2 2025 Results).
The competitive landscape has intensified following the FDA's accelerated approval of sunvozertinib (Zegfrovy) on July 2, 2025, which achieved a 46% overall response rate and an 11.1-month median duration of response in platinum-pretreated EGFR exon 20 insertion NSCLC, posing a threat to ArriVent’s potential market share for furmonertinib (FDA).
ArriVent faces over a year of binary trial risk, as topline results from the pivotal FURVENT Phase 3 study of furmonertinib in first-line EGFR exon 20 insertion NSCLC are not expected until early 2026 (Investing.com).
Despite ending Q2 2025 with $254.5 million in cash and investments and an $81.1 million offering in July, the expenditures for two global Phase 3 studies and multiple ADC trials will increase cash burn, likely requiring further external funding before commercialization (ArriVent Q2 2025 Results).
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.

AVBP Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

AVBP Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AVBP

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs